Gaig, C, Compta, Y, Heidbreder, A, Marti, MJ, Titulaer, MJ, Crijnen, Y, Hogl, B, Lewerenz, J, Erro, ME, Garcia-Monco, JC, Nigro, P, Tambasco, N, Patalong-Ogiewa, M, Erdler, M, Macher, S, Berger-Sieczkowski, E, Hoftberger, R, Geis, C, Hutterer, M, Milan-Tomas, A, Martin-Bastida, A, Manzanares, LL, Quintas, S, Hoglinger, GU, Mohn, N, Schoberl, F, Thaler, FS, Asioli, GM, Provini, F, Plazzi, G, Berganzo, K, Blaabjerg, M, Bruggemann, N, Farias, T, Ng, CF, Giordana, C, Herrero-San Martin, A, Huebra, L, Kotschet, K, Liendl, H, Montojo, T, Morata, C, Perez, JP, Puertas, I, Seifert-Held, T, Seitz, C, Simabukuro, MM, Tellez, N, Villacieros-Alvarez, J, Willekens, B, Sabater, L, Iranzo, A, Cano, JS, Dalmau, J, Graus, F. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease. NEUROLOGY. 2021; 97(14)DOI:10.1212/WNL.0000000000012639. PMID:34380749. IF:12.258(Q1/1D).

Pagano, G, Boess, FG, Taylor, KI, Ricci, B, Mollenhauer, B, Poewe, W, Boulay, A, Anzures-Cabrera, J, Vogt, A, Marchesi, M, Post, A, Nikolcheva, T, Kinney, GG, Zago, WM, Ness, DK, Svoboda, H, Britschgi, M, Ostrowitzki, S, Simuni, T, Marek, K, Koller, M, Sevigny, J, Doody, R, Fontoura, P, Umbricht, D, Bonni, A, PASADENA Investigators, Bejr-Kasem, H, Bojarsky J.K., Prasinezumab Study Grp. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Frontiers in Neurology. 2021; 12DOI:10.3389/fneur.2021.705407. PMID:34659081. IF:4.086(Q2/5D).

De Paepe, AE, Ara, A, Garcia-Gorro, C, Martinez-Horta, S, Perez-Perez, J, Kulisevsky, J, Rodriguez-Dechicha, N, Vaquer, I, Subira, S, Calopa, M, Munoz, E, Santacruz, P, Ruiz-Idiago, J, Mareca, C, de Diego-Balaguer, R, Camara, E. Gray Matter Vulnerabilities Predict Longitudinal Development of Apathy in Huntington's Disease. MOVEMENT DISORDERS. 2021; 36(9)DOI:10.1002/mds.28638. PMID:33998063. IF:9.698(Q1/1D).

Pagonabarraga, J, Tinazzi, M, Caccia, C, Jost, WH. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature. JOURNAL OF CLINICAL NEUROSCIENCE. 2021; 90DOI:10.1016/j.jocn.2021.05.056. PMID:34275546. IF:2.116(Q4/9D).

Diego, SG, Teresa, DD, Cores, C, Canfield, H, Paz Gonzalez, JM, Miro, CM, Aymerich, LV, Suarez, E, Jesus, S, Aguilar, M, Pastor, P, Planellas, L, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Hernandez-Vara, J, Cabo, I, Manzanares, LL, Aramburu, IG, Avila Rivera, MA, Catalan, MJ, Nogueira, V, Puente, V, Dotor, J, Borrue, C, Solano, B, Alvarez Sauco, M, Vela, L, Escalante, S, Cubo, E, Carrillo, F, Martinez Castrillo, JC, Alonso, PS, Alonso, G, Ariztegui, NL, Gaston, I, Kulisevsky, J, Blazquez, M, Seijo, M, Ruiz Martinez, J, Valero, C, Kurtis, M, de Fabregues, O, Ardura, J, Alonso, R, Ordas, C, Diaz, LML, McAfee, D, Martinez-Martin, P, Mir, P, COPPADIS Study Group. Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up. Journal of Personalized Medicine. 2021; 11(7)DOI:10.3390/jpm11070626. PMID:34209166. IF:3.508(Q2/4D).

Dam, T, Golbe, LI, Hoglinger, GU, Grundman, M, Yang, LL, Tidemann-Miller, B, Kupferman, J, Harper, K, Kamisoglu, K, Wald, MJ, Graham, DL, Gedney, L, O'Gorman, J, Haeberlein, SB, Aiba, I, Antonini, A, Apetauerova, D, Azulay, JP, Martinez, EB, Bang, J, Barone, P, Barrett, M, Bega, D, Berg, D, Corrales, KB, Bordelon, Y, Boxer, AL, Brandt, M, Brueggemann, N, Castelnovo, G, Ceravolo, R, Chuang, RD, Chung, SJ, Church, A, Corvol, JC, Cudia, P, Dale, M, Defebvre, L, Drapier, S, Driver-Dunckley, ED, Ebersbach, G, Eggert, KM, Ellenbogen, A, Eusebio, A, Evans, AH, Fedorova, N, Finger, E, Foubert-Samier, A, Ghosh, B, Golbe, L, Perez, FG, Grossman, M, Hall, D, Hamada, K, Hasegawa, K, Hoeglinger, G, Honig, L, Houghton, D, Huang, XM, Isaacson, S, Koh, S, Bojarski, JK, Lang, ANE, Leigh, PN, Litvan, I, Lozano, JJL, Moreno, JLLS, Ludolph, AC, Piudo, MRL, Torres, IM, McFarland, N, Meissner, W, Mestre, T, Rivera, PM, Molho, E, Mollenhauer, B, Morris, HR, Murata, M, Obi, T, Magne, FO, O'Suilleabhain, P, Pahwa, R, Pantelyat, A, Pavese, N, Pokhabov, D, Prudlo, J, Rodriguez-Porcel, F, Rowe, J, Savitt, J, Schnitzler, A, Schulz, JB, Seppi, K, Shah, BI, Shill, H, Shprecher, D, Stamelou, M, Steiger, M, Takahashi, Y, Takigawa, H, Tartaglia, C, Toenges, L, Truong, D, Tse, W, Tuite, P, Volc, D, Wills, AMA, Woitalla, D, Xie, T, Yuasa, T, Zauber, SE, Zesiewicz, T. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021). NATURE MEDICINE. 2023; 29(11)DOI:10.1038/s41591-022-02076-8. PMID:36253611. IF:58.700(Q1/1D).

Martinez-Horta, S, Marzal-Espi, CN, Cuso-Garcia, S, Aracil-Bolanos, I, Kulisevsky, J. Reduplicative paramnesia as an atypical form of presentation of a Heidenhain variant of Creutzfeldt-Jakob disease: A case report. JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY. 2023; 29(6)DOI:10.1017/S1355617722000583. PMID:36062534. IF:2.600(Q2/4D).

Rossi M., Hamed M., Rodríguez-Antigüedad J., Cornejo-Olivas M., Breza M., Lohmann K., Klein C., Rajalingam R., Marras C., van de Warrenburg B.P.. Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review. MOVEMENT DISORDERS. 2023; 38(3)DOI:10.1002/mds.29278. PMID:36374860. IF:7.400(Q1/1D).